Oxford BioDynamics (OBD) AI Stock Analysis

• Market Cap: £6.26M
• Dividend Yield: N/A
• Average Volume (3M): 21.87M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.34
• Revenue Growth: 45.22%
• EPS Growth: 55.71%
• Country: UK
• Employees: 51
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 1,957,577,600
• 10 Day Avg. Volume: 50,883,470
• 30 Day Avg. Volume: 21,870,725
• PEG Ratio: 0.02
• Price to Book (P/B): 1.89
• Price to Sales (P/S): 12.95
• P/FCF Ratio: -0.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: 0.50p ▲(92.31% Upside)

Oxford BioDynamics' stock score is primarily impacted by its challenging financial performance, characterized by consistent losses and negative cash flows. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable due to a negative P/E ratio. These factors collectively suggest a high-risk investment with significant financial and operational challenges.

Positive Factors

Revenue Growth

The company has demonstrated strong revenue growth, indicating successful market penetration and increasing demand for its biomarker tests.

Strategic Collaborations

Partnerships with pharmaceutical companies and research institutions bolster market position and drive innovation, supporting long-term growth.

Proprietary Technology

The EpiSwitch® platform provides a competitive edge in biomarker development, enhancing the company's ability to offer unique and valuable clinical insights.

Negative Factors

Consistent Net Losses

Ongoing net losses indicate operational inefficiencies and high costs, which can hinder long-term financial stability and growth potential.

Negative Cash Flows

Persistent negative cash flows suggest difficulties in sustaining operations without external financing, posing a risk to financial health.

Rising Leverage

Increased leverage heightens financial risk, potentially limiting flexibility and increasing vulnerability to economic downturns.

Oxford BioDynamics Business Overview & Revenue Model

Company Description

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.

How the Company Makes Money

Oxford BioDynamics generates revenue primarily through the sale of its biomarker tests and services, which are utilized by pharmaceutical companies, research institutions, and healthcare providers. The company's key revenue streams include fees for conducting epigenetic testing and analysis, licensing agreements for its proprietary technology, and collaborations with pharmaceutical companies for the development of companion diagnostics. Additionally, OBD may receive funding through research grants and partnerships aimed at advancing epigenetic research, which further contributes to its earnings. Strategic collaborations with industry leaders enhance its market presence and facilitate revenue growth.

Oxford BioDynamics Financial Statement Overview

Summary

Oxford BioDynamics faces substantial financial challenges with consistent net losses, negative cash flows, and rising leverage. The financial trajectory suggests potential liquidity and solvency concerns, requiring strategic intervention.

Income Statement

Oxford BioDynamics shows a challenging financial trajectory with consistent net losses over the past years. The gross profit margin is low, and net income has been negative, indicating unprofitability. Revenue growth has been erratic, with no clear upward trend. EBIT and EBITDA margins are negative, reflecting operational inefficiencies and high costs relative to revenue.

Balance Sheet

The balance sheet presents concerns, particularly in rising debt levels relative to equity, which has led to a rising debt-to-equity ratio. Return on equity is negative due to consistent net losses, and the equity ratio has decreased, indicating increased leverage and financial risk. However, there is still some equity cushion available, albeit shrinking.

Cash Flow

Cash flow analysis indicates significant strains with negative free cash flow and operating cash flow over the years. There was a notable decline in free cash flow growth rate, highlighting cash generation issues. Operating cash flow to net income ratio is negative, reinforcing operational cash challenges. Financing activities have been critical in supporting cash needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	896.00K	636.00K	510.00K	154.00K	341.00K	456.00K
Gross Profit	-6.39M	289.00K	266.00K	116.00K	-557.00K	-166.00K
EBITDA	-10.98M	-10.27M	-9.84M	-6.16M	-6.43M	-4.42M
Net Income	-12.59M	-11.57M	-10.83M	-6.71M	-6.68M	-4.31M
Balance Sheet
Total Assets	13.30M	12.11M	16.13M	11.34M	15.38M	15.35M
Cash, Cash Equivalents and Short-Term Investments	4.26M	2.83M	5.25M	999.00K	4.34M	11.51M
Total Debt	5.14M	5.74M	6.44M	6.14M	6.59M	541.00K
Total Liabilities	7.37M	7.75M	10.07M	8.76M	8.69M	1.77M
Stockholders Equity	5.93M	4.36M	6.05M	2.59M	6.68M	13.56M
Cash Flow
Free Cash Flow	-11.69M	-10.77M	-9.01M	-6.08M	-9.01M	-3.86M
Operating Cash Flow	-11.68M	-10.17M	-8.29M	-5.18M	-5.92M	-3.40M
Investing Cash Flow	-480.00K	-1.49M	-691.00K	1.25M	2.83M	4.58M
Financing Cash Flow	15.24M	8.25M	13.42M	2.56M	-804.00K	-181.00K

Oxford BioDynamics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OBD, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.36, and below the 200-day MA of 0.42, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 37.91 is Neutral, neither overbought nor oversold. The STOCH value of 28.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:OBD.

Oxford BioDynamics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FAB	58 Neutral	£17.33M	―	-164.37%	―	-11.43%	23.40%
AREC	56 Neutral	£27.94M	-3.35	-204.29%	―	3.31%	21.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IXI	48 Neutral	£10.43M	-4.83	-15.57%	―	7.27%	39.64%
APTA	46 Neutral	£22.25M	-5.89	-213.66%	―	39.88%	81.33%
OBD	40 Underperform	£6.26M	-0.11	-333.59%	―	45.22%	55.71%

Oxford BioDynamics Corporate Events

Oxford BioDynamics’ Study on Predictive Cancer Test: Market Implications

Oxford BioDynamics is conducting a study titled A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications. The study aims to assess the effectiveness of the Episwitch CiRT® test in predicting cancer patients’ responses to PD-(L)-1 checkpoint inhibitors, a type of immunotherapy.

Oxford BioDynamics Launches £7 Million Fundraising Initiative

Oxford BioDynamics has announced a fundraising initiative to raise £7 million through a placing and subscription of new ordinary shares. This funding is crucial for the company to support its operations and pursue additional business development opportunities. The funds will help the company continue its growth in PSE test sales, further develop its EpiSwitch KnowledgeBase in partnership with Google Cloud, and engage in third-party partnerships and collaborations. The fundraising is contingent on shareholder approval at a general meeting, and failure to secure this funding could necessitate alternative financial arrangements or a potential sale of the business.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics’ EpiSwitch PSE Recognized in Prostate Cancer Screening Report

Oxford BioDynamics has been highlighted in a new report by Prostate Cancer Research, which supports the feasibility of a targeted prostate cancer screening program in the UK. The report recommends the inclusion of emerging technologies like OBD’s EpiSwitch PSE blood test in the NHS, citing its potential to significantly reduce false positives and unnecessary diagnostic procedures. The EpiSwitch PSE test, with its high specificity, could decrease the demand for MRI and biopsy procedures, thereby saving costs for the NHS and making large-scale screening more practical.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics Unveils Breakthrough Blood Test for Chronic Fatigue Syndrome

Oxford BioDynamics has developed a groundbreaking blood test for diagnosing Chronic Fatigue Syndrome (CFS) with a high accuracy of 96%, offering a reliable diagnostic tool for a condition that affects millions globally and has long been misunderstood. This advancement, achieved using the company’s EpiSwitch® 3D genomics platform, not only promises to improve diagnosis and management of CFS but also paves the way for similar tests for conditions like long Covid, enhancing Oxford BioDynamics’ positioning in the precision diagnostics industry.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics’ EpiSwitch CiRT Test Shows Promise in Clinical Treatment Decisions

Oxford BioDynamics has announced interim results from its PROWES trial, showcasing the clinical utility of its EpiSwitch CiRT test in guiding treatment decisions for patients undergoing immune checkpoint inhibitor therapy. The study, published in the journal Cancers, demonstrated that the CiRT test influenced treatment choices in 61% of cases, helping oncologists make more informed decisions. The test’s ability to predict patient responses with high sensitivity and specificity could lead to significant cost savings by avoiding ineffective treatments. The company plans to apply for inclusion in the US National Comprehensive Cancer Network clinical guidelines, aiming for broader adoption and commercial success.

The most recent analyst rating on (GB:OBD) stock is a Hold with a £0.50 price target. To see the full list of analyst forecasts on Oxford BioDynamics stock, see the GB:OBD Stock Forecast page.

Oxford BioDynamics Partners with Google Cloud to Advance Genomic Analytics

Oxford BioDynamics has announced a collaboration with Google Cloud to enhance its cloud-based analytical frameworks for precision medicine. This partnership will allow OBD to scale its EpiSwitch® platform using Google Cloud’s infrastructure, facilitating high-throughput, AI-powered 3D genomic analytics. The collaboration is expected to improve OBD’s digital transformation, enabling faster insights and broader access for its pharmaceutical and biotech partners, while also creating opportunities for future commercialization of its platform.